How are pharmaceutical companies redefining success in low- and middle-income countries (LMICs) as both access priorities and market opportunities evolve?
Rabin Martin conducted interviews with two dozen experts from 13 of the largest pharmaceutical companies working in market access and strategy roles across the industry. The goal was to understand better how these companies are navigating the complexity of LMICs, where traditional models don’t always apply and success looks different than in high-income settings.
Interviewees shared practical insights on operating models, team structures, partnerships, and what it takes to deliver both innovation and impact in these complex markets. Their perspectives reflect a wide range of experiences yet share common themes, tensions, and lessons. Download the report to see what we learned.